IMR Press / EJGO / Volume 30 / Issue 4 / pii/2009095

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia

Show Less
1 University at Buffalo School of Medicine, Buffalo, NY (USA)
2 Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY (USA)
Eur. J. Gynaecol. Oncol. 2009, 30(4), 387–388;
Published: 10 August 2009

Pegylated liposomal doxorubicin (PLD) is an effective and tolerable agent in the treatment of recurrent and refractory ovarian car-cinoma. One of the most common dose-limiting toxicities of PLD is palmar-plantar erythrodysesthesia (PPE). We report a retro-spective review of patients who took cod liver oil (CLO) while being treated with PLD at Roswell Park Cancer Institute. None of the patients required dose reduction, treatment interruption or discontinuation secondary to skin toxicity. No patient experienced grade 2 or greater PPE. The mechanism for the development of PLD-induced PPE is unknown. CLO may possibly mitigate it via decreased extravasation of PLD and/or by a blunting of the local inflammatory response. The effects of CLO should be further eval-uated in a prospective, randomized trial, and attempts to elucidate the mechanism by which CLO may exert its effects should be pursued.

Pegylated liposomal doxorubicin
Palmar-plantar erythrodysesthesia
Cod liver oil
Back to top